N-Acetylation polymorphism as a risk factor for lung adenocarcinoma; In relation to p53 gene mutation

Oyama, Tsunehiro; Osaki, Toshihiro; Nose, Naohiro; Ichiki, Yoshinobu; Uramoto, Hidetaka; Imoto, Hideyuki; Yoshimatsu, Takashi; Kodate, Mantaro; Yano, Koichi; Yasumoto, Kosei

doi:10.1016/s0169-5002(00)80781-3

Cited by 28 publications

(47 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CYP2E1*5 variant has increased enzyme activity, and that may lead more rapid activation of carcinogens, which could lead leukemic transformation [45]. Krajinovic et al reported that children carrying the CYP2E1*5 variant are at 2.8-fold increased risk for ALL [44]. However, the functional significance of this allele is not clear, according to our findings the patients carrying at least one CYP2E1*5 mutant allele were at risk of ALL and AML.…”

Section: Discussionmentioning

confidence: 48%

Role ofCYP2D6, CYP1A1, CYP2E1, GSTT1, andGSTM1 genes in the susceptibility to acute leukemias

Sayitoğlu¹,

Hatırnaz²,

Erensoy³

et al. 2006

Am. J. Hematol.

View full text Add to dashboard Cite

Acute leukemias (ALs) are heterogeneous diseases. Functional polymorphisms in the genes encoding detoxification enzymes cause inter-individual differences, which contribute to leukemia susceptibility. The CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 polymorphisms in ALL (n = 156) and AML (n = 94) patients and 140 healthy controls were genotyped by PCR and/or PCR-RFLP using blood or bone marrow samples. No association was observed between the GSTT1 gene deletion and patients (OR = 0.8, 95% CI = 0.4-1.7 for AMLs and OR = 0.9, 95% CI ¼ 0.5-1.6 for ALLs). Patients with ALL and AML had a higher prevalence of the GSTM1 deletions compared to controls but only the difference among adult AML patients (OR = 2.1, 95% CI = 1.0-4.2) was statistically significant. The CYP2D6*3 variant allele frequency was lower in the overall acute leukemia patients (0.6%) compared to controls (P = 0.03). CYP2D6*1/*3 genotype frequency also showed a protective association in AML patients (OR = 0.09, 95% CI = 0.01-1.7; P = 0.04). We also found a risk association for CYP2E1*5 in ALL and AML (OR = 3.6, 95% CI = 1.4-9.4 and OR = 3.9, 95% CI = 1.4-10.5, respectively). No association was found for the studied CYP2D6*4, CYP1A1*2A, and GSTT1''null'' variants and the risk of acute leukemia (ALL or AML). This case-control study suggests a contribution of CYP2E1, CYP2D6, and GSTM1 ''null'' variants to the development of acute leukemias. Am.

show abstract

Section: Discussionmentioning

confidence: 48%

Role ofCYP2D6, CYP1A1, CYP2E1, GSTT1, andGSTM1 genes in the susceptibility to acute leukemias

Sayitoğlu¹,

Hatırnaz²,

Erensoy³

et al. 2006

Am. J. Hematol.

View full text Add to dashboard Cite

show abstract

“…20) Another study in Japanese found a significantly high risk of CYP2E1 Rsa1 variant allele for lung SCC, but no association with lung AC. 47) Furthermore, one investigation in Chileans also found no association, 18) though only 8.3% of the cases were lung ACs. Our study was in accordance with the findings of Le Marchand et al, who observed an inverse association between the risk of lung ACs and CYP2E1 variant allele.…”

Section: Discussionmentioning

confidence: 97%

Association of GSTM1, CYP1A1 and CYP2E1 genetic polymorphisms with susceptibility to lung adenocarcinoma: A case‐control study in Chinese population

Wang

Deng

et al. 2003

Cancer Science

View full text Add to dashboard Cite

A case-control study of 164 lung adenocarcinoma (AC) patients with 181 age-and gender-matched healthy controls was conducted in order to assess any associations between glutathione-Stransferase M1 (GSTM1), cytochrome P4501A1 (CYP1A1) and cytochrome P4502E1 (CYP2E1) polymorphisms and susceptibility to lung AC in Chinese. The presence of CYP2E1 variant allele was significantly less frequent in cases than in controls, while the distribution of GSTM1 null genotype and variant CYP1A1 Msp1 allele did not vary between cases and controls. After adjustment for age, gender, smoking and all other genotypes, the CYP2E1 Rsa1 variant allele was significantly associated with decreased risk of lung AC [odds ratio 0.534 (95% confidence interval, 0.340-0.837)]. Furthermore, 3.0-fold increased risk was found in individuals with combined GSTM1 null genotype and CYP2E1 Rsa1 wild type versus those with combined GSTM1 non-null type and CYP2E1 variant allele. Our results suggest that CYP2E1 Rsa1 variant allele is associated with a decreased risk of lung AC, and combined GSTM1 null genotype and CYP2E1 Rsa1 wild type has a promoting effect on susceptibility to lung AC. (Cancer Sci 2003; 94: 448-452) hile lung cancer incidence is now decreasing in men in some countries, it still remains a major worldwide health problem, accounting for more than one-sixth of cancer deaths. 1) Furthermore, the incidence and proportion of lung adenocarcinoma (AC) cases have been increasing for several decades in many Asian, American and European countries, leading to a changing clinical picture characterized by early development of metastases.It is well established that lung cancers in men and women are largely attributable to cigarette smoking, and the trend for elevation of lung AC is also considered to be related to an increase in exposure to tobacco-specific nitrosamines (TSNAs) from low-tar cigarettes. However, it has also been reported that only less than 20% of smokers develop lung cancer, suggesting that genetic variations and other environmental factors also play important roles in determining individual differences in lung cancer susceptibility. 2)Genetic variations in metabolic activation or detoxification enzymes are thought to make a major contribution, including polymorphisms in glutathione-S-transferase M1 (GSTM1), cytochrome P4501A1 (CYP1A1) and cytochrome P4502E1 (CYP2E1). Although many studies have shown that GSTM1 null genotype and variant CYP1A1 alleles are associated with an increased risk of lung squamous cell carcinoma (SCC) independent of the ethnic background, the results regarding lung AC risk are still contradictory.3-11) A number of studies have also investigated the association of the genetic polymorphism of CYP2E1 with lung cancer, but the effects remain unclear. 6,[12][13][14][15][16][17][18][19][20][21][22] In the Chinese population, lung cancer is the leading cause of cancer deaths, and while SCC is still the predominant histological type, the rate for lung AC is increasing and AC is already the most common histological t...

show abstract

“…Emerging evidence, although inconclusive, has shown that TP53 (Arg72Pro) polymorphism is not only associated with lung cancer risk but also influences patient response to platinum-based chemotherapy and survival (28)(29)(30)(31)(32)(33). Furthermore, associations have also been shown between polymorphisms of some CYP genes such as the CYP2E1 or CYP1A1 and TP53 gene in NSCLC (5,6,9,34,35).…”

Section: Introductionmentioning

confidence: 99%

Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients

et al. 2017

View full text Add to dashboard Cite

Background/aim: The association between polymorphisms of xenobiotic/drug metabolizing enzymes and TP53 and response to chemotherapy and survival of patients with nonsmall cell lung cancer (NSCLC) are limited and inconclusive. In this study, CYP2E1*5B, CYP2E1*6, CYP2E1*7B, GSTO1 (A140D), and TP53 (Arg72Pro) polymorphisms and response to platinum-based chemotherapy and survival in 137 advanced stage NSCLC patients were investigated.Materials and methods: Genetic polymorphism analyses were determined by polymerase chain reaction (PCR) coupled with restriction fragment length polymorphism (RFLP). Results:The patients with TP53 Pro/Pro variant were more likely to be resistant to chemotherapy than those with Arg/Arg variants with marginal significance (P = 0.066). We also analyzed these gene variants in combination with CYP1A1 (Ile462Val), CYP1B1 (Asn453Ser), GSTM1, GSTP1 exon 5 (Ile105Val), and GSTP1 exon 6 (Ala114Val) and GSTT1 polymorphic genes that we have previously genotyped in the same patients (Ada et al., Neoplasma, 57, 512-527, 2010). The multivariate analysis revealed that adjusted hazard ratio (HR) of death of the combined variant genotypes of TP53 (Arg72Pro, Pro72Pro) and CYP1A1 (Ile462Val, Val462Val) increased significantly as compared to wild-type genotypes (HR,

show abstract

N-Acetylation polymorphism as a risk factor for lung adenocarcinoma; In relation to p53 gene mutation

Cited by 28 publications

References 0 publications

Role ofCYP2D6, CYP1A1, CYP2E1, GSTT1, andGSTM1 genes in the susceptibility to acute leukemias

Role ofCYP2D6, CYP1A1, CYP2E1, GSTT1, andGSTM1 genes in the susceptibility to acute leukemias

Association of GSTM1, CYP1A1 and CYP2E1 genetic polymorphisms with susceptibility to lung adenocarcinoma: A case‐control study in Chinese population

Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients

Contact Info

Product

Resources

About